.png)
.svg)
Drug Resistance Summit
May 12–14, 2027
Chicago, Illinois
Invitation Only
Mechanisms
of Resistance.
A working summit on how hematologic and solid malignancies evade therapy — clonal evolution, immune escape, epigenetic reprogramming, and the RAS pathway — and the strategies emerging to stay ahead of them.
Dates
May 12–14, 2027
Welcome Networking · Wed 12 May
Venue
Pendry Chicago
Michigan Avenue · Illinois
Focus
Drug Resistance
Heme & solid tumor
01 — Overview
Understanding how cancer adapts.
Co-Chair
Sanam Loghavi, MD
MD Anderson Cancer Center
Co-Chair
Ann-Kathrin Eisfeld, PhD
Bloomfield Center for Leukemia Outcomes Research at The Ohio State University
Resistance is the common thread across modern oncology.
Across leukemias, lymphomas, myeloma, and solid tumors, the mechanisms that let disease escape therapy increasingly rhyme — clonal evolution under pressure, immune evasion, non-genetic and epigenetic adaptation, and convergent pathways like RAS.
This summit brings clinical and translational investigators together around those shared mechanisms, deliberately crossing disease boundaries so that lessons from one setting inform the next.
SCIENTIFIC ADVISOR
Naval Daver, MD
MD Anderson Cancer Center
SCIENTIFIC ADVISOR
Elias Jabbour, MD
MD Anderson Cancer Center
02 — Schedule
Three days,in Chicago.
12
May
Wednesday
Welcome Networking
Evening
13
May
thursday
Day One
Clonal Evolution Under Therapeutic Pressure · Resistance to Targeted Therapies · Immune Evasion and CAR-T Resistance
3 sessions · 3 symposia · Group dinner
14
May
friday
Day Two
Epigenetic and Non-Genetic Resistance · MRD-Guided Therapy · Lessons From Solid Tumors · RAS Across the Spectrum
3 sessions · 3 symposia · Closing
03 — The Program
Six resistance themes.
Open any theme to see its talks & speakers · session times to be scheduled
Day 1
Wed · 13 May
Day 2
Thu · 14 May
Program in development · order, FACULTY & timing subject to change
Expand all sessions
7:30 AM
Registration · Light breakfast on tables
8:00 AM
Welcome & Chair Remarks · Dr. Naval Daver & Dr. Elias Jabbour
01
Track 01 · 4 talks
Clonal Evolution Under Therapeutic Pressure
Theme
Myeloma
TBD
MD Anderson Cancer Center
AML
cfDNA in AML
MD Anderson Cancer Center
MDS
TBD
MD Anderson Cancer Center
Myelofibrosis
Mechanisms of resistance to JAK inhibitors and avenues to overcome resistance
Montefiore Einstein
02
Track 02 · 9 talks
Resistance to Targeted Therapies: BCL-2, BTK, IDH, FLT3 and Next-Generation Inhibitors
Theme
CLL
Beyond BTKs: Non-Covalent Inhibitors, Degraders, and the Path Past Resistance
MD Anderson Cancer Center
Mantle cell lymphoma
New therapeutic approaches in mantle cell lymphoma
City of Hope
AML
Overcoming IDHi resistance in AML
Washington University
AML
Venetoclax/decitabine resistance linked to fatty acid metabolism
Roswell Park
LUNG CANCER SOLID TUMOR
TBD
Memorial Sloan Kettering
AML
FLT3 inhibitor resistance
MD Anderson Cancer Center
Ph+ ALL
Optimizing outcome with chemo free regimens, are risking emergence of resistant clones?
MD Anderson Cancer Center
BPDCN / AML
CD123-based therapies and mechanisms of resistance in BPDCN and AML
MD Anderson Cancer Center
DLBCL
Lessons learned from AUGMENT
MD Anderson Cancer Center
03
Track 03 · 7 talks
Immune Evasion and Resistance to CAR-T Cell Therapy
Theme
T cell exhaustion/TME
T Cell Exhaustion: A Barrier to Effective Immunotherapy
MD Anderson Cancer Center
BALL
Outcomes post CD19 immune therapy failure
Cambridge
ALL
CAR-T/Blina/Inotuzumab resistance
MD Anderson Cancer Center
T-ALL
T-ALL: Resistance Mechanisms and New Therapeutic Approaches
MD Anderson Cancer Center
DLBCL/lymphoma
CAR-T resistance in aggressive B cell lymphomas
MD Anderson Cancer Center
Myeloma
Cellular therapies in myeloma
MD Anderson Cancer Center
NK
Harnessing NK Cells to Overcome Treatment Resistance
NYU Langone Health
04
Track 04 · 4 talks
Epigenetic Reprogramming and Non-genetic Resistance Mechanisms
Theme
AML/myeloid neoplasms
Current state of menin inhibitors in clinical practice
Peter MacCallum Cancer Centre
MDS/AML
METTL3 trials
Dana-Farber Cancer Institute
AML
A new era of menin inhibition and clinical implications
Dana-Farber Cancer Institute
AML
Overcoming mechanisms of resistance to menin inhibitors
University of California, San Francisco
05
Track 05 · 4 talks
Resistance in the Context of MRD-Guided Therapy
Theme
AML
MRD-Guided Therapy in AML: Tracking and Overcoming Resistance
Memorial Sloan Kettering
CLL
Resistance in the Era of MRD-Guided CLL Treatment
MD Anderson Cancer Center
Myeloma
MRD-Guided Therapy in Myeloma: Tracking and Overcoming Resistance
Memorial Sloan Kettering
Solid tumor MRD
Early Detection of MRD in Solid Tumors: Methods and Challenges
MD Anderson Cancer Center
06
Track 05 · 5 talks
Lessons learned from solid tumors and beyond
Theme
Checkpoint inhibitors
Checkpoint Inhibitors: Lessons in Resistance from Solid Tumors
Memorial Sloan Kettering
Pancreatic Cancer
Understanding Therapeutic Resistance in Pancreatic Cancer
MD Anderson Cancer Center
Colorectal Cancer
Resistance to Targeted Therapy in Colorectal Cancer
Memorial Sloan Kettering
CML
Lessons learned from TKi resistance in CML
MD Anderson Cancer Center
Solid tumor MRD
Mutation-agnostic therapies in solid tumors
MD Anderson Cancer Center
10:00 pM
Sponsor Symposium 1
BPDCN in 2026: Diagnosis, Targeted Therapy, and the Path Forward
10:30 AM
Coffee Break
12:00 PM
Sponsor Symposium 2 · Lunch
FLT3-Mutated Acute Leukemia: Case-Based Approaches to Frontline and Relapsed Disease
12:45 PM
Networking Lunch
2:30 PM
Sponsor Symposium 3
Fixed-Duration Therapy in Treatment-Naïve CLL: The Evolving Role of uMRD as a Clinical Endpoint
4:15 PM
Day 1 Wrap & Chair Remarks · Dr. Naval Daver & Dr. Elias Jabbour
Evening
Group Dinner · Faculty and partners
07
Track 06 · 5 talks
RAS Across the Spectrum: Heme, Solid Tumor, and Therapeutic Horizons
Theme
Targeting RAS in solid tumors
Drugging RAS in Solid Tumors: Challenges and Opportunities
NYU Langone Health
Developing RASi
Developing RAS Inhibitors: From Bench to Clinic
Revolution Medicines
Targeting the RASp in AML and myeloid neoplasms
Targeting the RAS Pathway in AML and Myeloid Neoplasms
Stanford Medicine
The role of RASp in extramedullary AML
RAS Pathway Signaling in Extramedullary AML
OSU
The role of RASp in extramedullary AML
RAS Pathway Signaling in Extramedullary AML
Montefiore Einstein
Targeting RAS and overcoming resistance
Targeting RAS and overcoming resistance
Montefiore Einstein
8:00 AM
Arrival · Coffee and light breakfast
9:00 AM
Day 2 Chair Remarks · Dr. Naval Daver & Dr. Elias Jabbour
06
Session 06 · 9:15 AM
Future Directions in AML Therapy
AML
CD123 and CD33 targeting in AML: bench to bedside
MOFFITT CANCER CENTER
MRD as endpoint and MRD-based therapies in AML: myth or reality?
MD ANDERSON CANCER CENTER
Using FLT3 MRD to guide treatment in FLT3-mutated AML
Fralin Biomedical Research Institute, VTC
Immune and inflammatory drivers of AML: therapeutic opportunities
MD ANDERSON CANCER CENTER
CASE
MDS case-based discussion
Huntsman Cancer Institute
panel
Panel discussion
10:15 AM
Sponsor Symposium 4
Menin Inhibition in Acute Leukemias: Emerging Data, Resistance Mechanisms, and Rational Combinations
10:45 AM
Coffee Break
07
Session 07 · 11:00 AM
Optimizing Outcomes in R/R ALL
r/r all
CASE
How to sequence options: case-based discussion
MD Anderson Cancer Center
Novel agents in R/R ALL
City of Hope
PRO
Debate: CAR-T as definitive therapy or bridge to allo-SCT
Memorial Sloan Kettering
CON
Debate: CAR-T as definitive therapy or bridge to allo-SCT
Moffitt Cancer Center
panel
Panel discussion
12:00 PM
Sponsor Symposium 5 · Lunch
Optimizing ALL therapy and how to sequence immunotherapies
12:45 PM
Networking Lunch
08
Session 08 · 1:30 PM
ALL Personalized Therapy
All
Genomic classification of ALL
University of Nebraska Medical Center
Myeloid mutations in ALL: a new entity
MD Anderson Cancer Center
Ph-like ALL
Children's Hospital of Philadelphia
T-cell ALL, ETP, and near-ETP
University of Rochester
panel
Panel discussion
2:30 PM
Sponsor Symposium 6
Targeting the Menin Pathway: Post-EHA Perspectives in Acute Leukemia
09
Session 09 · 3:00 PM
Optimizing Frontline AML — Uses of Venetoclax
Aml
The ideal molecular classification of frontline AML in clinical practice
MD Anderson Cancer Center
AZA-VEN in younger patients: changing the paradigm
University of Colorado School of Medicine
Improving conditioning by incorporating venetoclax pre-alloSCT
MD Anderson Cancer Center
PRO
Debate: Venetoclax-based triplet vs doublet in frontline FLT3-ITD AML, non-IC
MD Anderson Cancer Center
Con
Debate: Venetoclax-based triplet vs doublet in frontline FLT3-ITD AML, non-IC
Northwestern Medicine
panel
Panel discussion
4:15 PM
Closing Remarks · Summit Adjourns ·Dr. Naval Daver & Dr. Elias Jabbour
04 — Key Opinion Leaders
Co-Chairs & Faculty.
Co-Chair
Ioannis Aifantis, PhD
NYU Langone Health
Co-Chair
Sanam Loghavi, MD
MD Anderson Cancer Center
Ioannis Aifantis
NYU Langone Health
FACULTY
Ioannis Aifantis
NYU Langone Health
IN THE PROGRAM
No items found.
Jim Allison
MD Anderson Cancer Center
FACULTY
Jim Allison
MD Anderson Cancer Center
IN THE PROGRAM
No items found.
Jessica Altman
MD Anderson Cancer Center
FACULTY
Jessica Altman
MD Anderson Cancer Center
IN THE PROGRAM
No items found.
Scott Armstrong
Memorial Sloan Kettering
FACULTY
Scott Armstrong
Memorial Sloan Kettering
IN THE PROGRAM
No items found.
Kelly Bolton
Washington University
FACULTY
Kelly Bolton
Washington University
IN THE PROGRAM
No items found.
MD Anderson · Memorial Sloan Kettering · Dana-Farber · NYU Langone · Penn · Moffitt · Mayo · Washington University · Ohio State · Peter MacCallum · Montefiore Einstein · Stanford · Weill Cornell · Baylor · Roswell Park · Mass General · Revolution Medicines
05 — Founding Partners
Made possible by our partners.
The Drug Resistance Summit is now inviting its founding partners. Confirmed organizations will be recognized across the tiers below.
Founding Lead Partners
Major Partners
Partners
SUPPORTERS
04 — Partnership Opportunities
Four Founding Tiers.
A selective platform to connect with established thought leaders & future innovators
Founding Lead Partner
8 passes
Choice of private Welcome Reception or private breakfast (Thursday or Friday), first pick
45-minute symposium, first choice of slot and day
30-minute pre-summit program and logistics briefing with the organizing team
Comprehensive Faculty Compendium
Dedicated private meeting room for the full summit
Reserved seating at the summit group dinner
Post-summit insights report, and executive summary
Premium exhibitor space
Exhibitor table
Signature item branding
Bag insert
Logo on platform and signage
Founding Major Partner
6 passes
Private breakfast, Thursday or Friday, one per partner
30-minute symposium, second choice of slot
30-minute pre-summit program and logistics briefing with the organizing team
Reserved seating at the summit group dinner
Post-summit executive summary
Exhibitor table
Key card branding
Bag insert
Recognition in conference materials
Logo on platform and signage
Founding
Partner
Partner
5 passes
30-minute symposium, remaining slots
Exhibitor table
Bag insert
Recognition in conference materials
Lanyard branding
05 — Additional Opportunities
Beyond The
Meeting.
Insight and access that extend the value of the summit before, during and after Chicago
Meeting Insights Report
What the faculty said, and what it means.
.svg)
Synthesis across all six resistance themes
Consensus, controversy and unmet-need mapping
Audience polling and Q&A analysis
Delivered within three weeks of the meeting
Konstellate Opinion Leader Intelligence
Access to the platform behind the KOL Network.
Full profiles of every summit faculty member: publications, congress activity, trials, social
Topic tracking across menin, RAS, MRD, CAR-T and BCL-2 resistance
Sentiment and share-of-voice analytics
OLI, the AI research assistant, grounded in the platform's evidence
Meeting Content Library
Exclusive to one sponsor.
Recordings and approved slides from all independent-program sessions
Transcripts indexed by theme, speaker and topic
Use Konstellate and Ask OLI what the faculty said on any resistance question
Faculty Compendium
Know who's in the room before you arrive.
Bios, research focus and active trials for every speaker
Recent publications and presentations
Delivered four weeks ahead, print and digital
Advisory Boards
Structured expert engagement adjacent to the summit.
Recruitment from summit faculty, independent moderation, full logistics
Written summary report
Contracted separately at fair market value; agenda based on documented scientific need
Scientific Roundtables
Small-group discussion on a single resistance question.
Six to ten faculty, 60 minutes, onsite or virtual
Non-promotional scientific exchange format
Written summary of discussion
Contracted separately
06 — Venue
Chicago, Illinois.
Pendry Chicago
Michigan Avenue · 60601
Dates
Wednesday–Friday, 12–14 May 2027
Welcome Networking · Wednesday 12 May, evening
Venue
Pendry Chicago
Michigan Avenue, Chicago, Illinois
Focus
Mechanisms of drug resistance
Hematologic & solid malignancies · translational
Inquiries
07 — Continuing the Conversation
Get in touch.
Next
A KOL Network Meeting
The Drug Resistance Summit follows the NextGen Heme Summit in the KOL Network series of invitation-only convenings in hematologic oncology.
May 2027 · PENDRY Chicago
TBA
Participation is reserved for invited healthcare professionals and partners. For registration and sponsorship enquiries, contact us at:
info@thekolnetwork.comthekolnetwork.com